Evaluation of systemic inflammation- and nutrition-based indices in the prediction of HPV persistence Authors: Fatma Ozmen, Burcu Ozata, Burcu Erol Published: 2025 ABSTRACT AbstractAimPersistent high-risk human papillomavirus (HPV) infection is the primary etiological factor in cervical cancer, with HPV16 and HPV18 posing the greatest oncogenic risk. Although systemic inflammation and nutritional indices such as the Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) score and Prognostic Nutritional Index (PNI) have prognostic value in various malignancies, their role in predicting HPV persistence remains unclear. This study aimed to evaluate the predictive value of HALP and PNI scores for one-year HPV persistence and additionally assessed other inflammatory markers, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and C-reactive protein (CRP).MethodsThis retrospective study included 470 HPV-positive women aged 31–67 years who were followed for at least one year between January 2021 and March 2025. Participants were categorized into Group N (HPV clearance, n = 271) and Group P (HPV persistence, n = 199) according to one-year HPV results. Baseline demographic, clinical, histopathological, and laboratory data were collected. HALP and PNI scores were calculated from hemoglobin, albumin, lymphocyte, and platelet counts, and inflammatory markers including NLR, PLR, and CRP were evaluated. Group comparisons were performed using appropriate statistical tests, and predictive performance was assessed using receiver operating characteristic (ROC) analysis. Continuous variables were standardized using Z-score transformation before multivariate logistic regression to minimize scale differences among predictors.ResultsWithin a year, 271 (57.7%) of the 470 women achieved viral clearance, whereas 199 (42.3%) had persistent infection. No substantial differences were observed in demographic or histological parameters. Vaccination after diagnosis did not affect clearance rates. The median HALP and PNI scores were similar between groups and provided no discriminatory ability [HALP AUC = 0.475 (95% CI: 0.422–0.528); PNI AUC = 0.487 (95% CI: 0.434–0.540)], as did PLR [AUC = 0.513 (95% CI: 0.460–0.566)] and CRP [AUC = 0.462 (95% CI: 0.409–0.515)]. In contrast, NLR was significantly higher in the persistence group (p < 0.001) and demonstrated modest discriminatory ability [AUC = 0.623 (95% CI: 0.573–0.673)]. HPV16 and HPV18 positivity was strongly associated with persistence. ConclusionsWhen the researchers evaluated the subjects’ systemic inflammatory and nutritional status, they found that HALP, PNI, PLR, and CRP did not provide effective predictive value for one-year HPV persistence. Conversely, NLR exhibited a promising capacity to function as a straightforward systemic inflammatory marker. The presence of HPV16 and HPV18 was found to be significantly associated with the persistence of the infection, thereby corroborating the established immune evasion mechanisms associated with these types. These findings underscore the necessity for prognostic markers that integrate both local mucosal immune responses and systemic inflammatory pathways to enhance risk stratification and management of HPV-related disease.Keywords: Human papillomavirus, HPV persistence, HALP score, Prognostic nutritional index, Cervical cancer, Prognostic biomarkers Introduction Cervical cancer (CC) is the fourth most prevalent type of cancer-related death for women globally [1]. CC is among the rare malignancies associated with a viral etiology, specifically human papillomavirus (HPV) infection [2]. CC is a type of cancer for which screening is possible through cervicovaginal cytology (CVC) and HPV testing. The natural history of most HPV infections is characterized by spontaneous resolution, typically occurring within 12 to 24 months without any notable clinical manifestations [3]. It is estimated that only 10–20% of infected women develop a persistent infection lasting longer than 24 months [4]. Failure to clear HPV infection may lead to persistence, which is a key driver of cervical intraepithelial neoplasia (CIN) and CC [5]. The formation of preinvasive lesions and the progression to malignant transformation can vary significantly at the individual level, depending on factors such as age, the type of HPV infection, smoking, and HIV infection [3, 6–8]. Nutritional status is known to significantly influence the immune system’s ability to mount an effective response against infections [9]. Hemoglobin, albumin, lymphocyte count, and platelet count values (HALP) and the Prognostic Nutritional Index (PNI) scores are noninvasive, low-cost prognostic indicators that comprehensively evaluate inflammation, nutritional status, and immune function based on hematological and immunological parameters. HALP and PNI scores are commonly used tools for predicting prognosis in malignant diseases and for assessing nutritional and immunological status [9–11]. In addition to these composite indices, simple hematological and biochemical markers such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and C-reactive protein (CRP) are also commonly investigated. NLR has been demonstrated to be a reliable indicator of the relationship between innate and adaptive immune responses. In contrast, PLR reflects the systemic inflammatory level, and CRP serves as a sensitive acute-phase reactant. The combination of these indicators offers supplementary insights into systemic inflammation and immunological processes [12–14]. The immune response, both local and systemic, plays a decisive role in the elimination of cervical HPV infection. Predicting HPV persistence may be a crucial tool for managing and keeping a watch on high-risk patients. The assessment of disease risk commonly employs a range of scientific approaches, including pathological techniques, medical imaging, laboratory analyses, and demographic data. However, the accuracy of these techniques in predicting HPV persistence remains unclear. These services have several important limitations, such as high costs, specialized knowledge, and the requirement for customized approaches. Therefore, this study aimed to evaluate the predictive value of HALP and PNI scores, along with hematological markers such as NLR, PLR, and CRP, in determining one-year HPV persistence. Patients and methods The present study was conducted in accordance with the Helsinki Declaration and approved by the Ethics Committee of the Faculty of Medicine, Ordu University (Approval No. 2025/152). Prior to analysis, all data were anonymized. From January 2021 to March 2025, a total of 581 HPV-positive female patients aged 31–67 years who had been subjects in the study for a minimum of one year were included in the analysis. We excluded 111 patients who underwent excisional treatment during the follow-up period, leaving a total of 470 patients in the study. The flow of patient inclusion and exclusion is presented in Fig. 1. Study flow diagram. Flow diagram of patient selection and grouping. A total of 581 HPV-positive women were initially assessed. Of these, 111 were excluded due to immune system disease or malignancy, long-term immunosuppressive or glucocorticoid therapy, incomplete test data, new cancer diagnosis during follow-up, control HPV test performed more than one year after baseline, or excisional treatment during follow-up. The remaining 470 patients were included in the final analysis and categorized into HPV clearance (Group N, n = 271) and HPV persistence (Group P, n = 199) The patients’ initial HPV tests were conducted as part of the Turkish National CC Screening Program, using DNA-based testing methods [SPF10, PCR-DEIA-LiPA25] and positive high-risk HPV tests [Hybrid Capture II (HC2)]. The initial HPV tests of the patients included in the study were performed within the scope of this program, and individuals with positive HPV results were referred to our center. Although different HPV testing methods (SPF10, PCR-DEIA-LiPA25, Hybrid Capture II, and Roche Cobas) were used during the study period as part of the national screening program, these assays are all validated for the detection of high-risk HPV types and demonstrate comparable sensitivity and specificity. Therefore, the results were considered compatible and suitable for combined analysis. All patients underwent colposcopic examination with cervical and endocervical sampling at the time of admission. Routine blood tests (Hb, WBC, lymphocyte, albumin) were obtained during admission as part of the standard pre-colposcopy evaluation. The laboratory data utilized in this retrospective study were obtained from the hospital information system. The demographic information collected included age, marital status, smoking status, chronic disease, contraceptive method, and mode of delivery. The laboratory parameters recorded included Hb, WBC, lymphocyte, platelet, CRP, and albumin. The results of the HPV test were then compared at the initial presentation and for one year. Initial HPV tests were evaluated using PCR, while cytology was assessed using the ThinPrep method (Hologic Inc., USA). A total of 15 HPV DNA genotypes were detected using the Roche Cobas system, including HPV16 and HPV18, ten additional high-risk types (31, 33, 35, 39, 45, 51, 52, 56, 58, and 59), and two lower-risk types (66 and 68). Cases with genotypes outside this panel were reported by the system as ‘HPV other.’ HPV genotyping was performed for all 470 patients at baseline and repeated at the one-year follow-up, enabling calculation of genotype-specific persistence. In cases where multiple HPV subtypes were detected simultaneously by the Cobas test, the classification was based on the presence of high-risk types. Patients with at least one high-risk HPV subtype, including HPV16 or HPV18, were categorized into the high-risk HPV group, regardless of the presence of additional low-risk subtypes. Cases that were HPV-positive at baseline were divided into two groups based on whether the HPV test became negative or remained positive at the first-year follow-up. The HALP and PNI scores were subsequently calculated and compared for both groups. A comparative analysis was conducted on the HALP and PNI scores between the two groups. To this end, both scores were calculated and subjected to statistical analysis to discern intergroup differences. The HALP score, which is based on hemoglobin, albumin, lymphocyte, and platelet values, was calculated as follows: HALP = (Hemoglobin [g/L] × Albumin [g/L] × Lymphocytes [/L])/Platelets [/L]. The PNI score was calculated as follows: PNI = (10 × Albumin [g/dL]) + (0.005 × Lymphocyte count [/mm³]) [9, 15]. NLR was calculated as the neutrophil-to-lymphocyte ratio and PLR as the platelet-to-lymphocyte ratio. The exclusion criteria are as follows: having an immune system disease, a diagnosis or history of malignancy, undergoing long-term glucocorticoid or immunosuppressive treatment, receiving treatment for another concurrent malignancy, possessing incomplete test data, being diagnosed with new cancer during follow-up that leads to the initiation of chemotherapy, and having a control HPV test performed more than one year ago. Statistics All statistical analyses were conducted using IBM SPSS Statistics for Windows, version 18.0 (IBM Corp., Armonk, NY, USA). The distribution of continuous variables was assessed with the Kolmogorov–Smirnov test. Variables following a normal distribution were expressed as mean ± standard deviation (SD), whereas non-normally distributed variables were presented as median and interquartile range (IQR). Between-group comparisons were made using the Student’s t-test for normally distributed variables and the Mann–Whitney U test for those not normally distributed. Categorical variables were summarized as numbers and percentages, and compared using the chi-square or Fisher’s exact test, where appropriate. While direct comparisons between the persistence and clearance groups (Table 1) were based on these univariate analyses, the predictive performance of HALP, PNI, and hematologic indices was further assessed using receiver operating characteristic (ROC) curve analysis and multivariate logistic regression (Table 2). To ensure comparability among continuous predictors measured on different scales, HALP, PLR, and NLR were standardized using Z-score transformation (mean = 0, SD = 1) before multivariate analysis. Odds ratios (OR) with 95% confidence intervals (CI) were calculated, and a two-tailed p-value < 0.05 was considered statistically significant. Table 1Comparison of systemic inflammation- and nutrition-based indices between clearance and persistence groups at one-year follow-upParameterGroup N (n = 271) Median (IQR)Group P (n = 199) Median (IQR)p-valueHALP49.11 (35.52–61.48)46.97 (35.77–58.40)0.361PNI55.30 (52.50–58.23)55.00 (52.20–58.10)0.637NLR1.16 (0.79–1.58)1.54 (0.99–2.18)< 0.001PLR117.7 (93.97–150.1)120.2 (98.37–149.6)0.642CRP (mg/L)2.69 (1.00–5.25)2.20 (0.90–4.60)0.158Values are presented as median (interquartile range). Between-group comparisons were performed using the Mann–Whitney U testAbbreviations: HALP Hemoglobin, Albumin, Lymphocyte, and Platelet score, PNI Prognostic Nutritional Index, NLR Neutrophil-to-Lymphocyte Ratio, PLR Platelet-to-Lymphocyte Ratio, CRP C-reactive Protein, IQR Interquartile Range. p-values were calculated using the Mann–Whitney U test Comparison of systemic inflammation- and nutrition-based indices between clearance and persistence groups at one-year follow-up Values are presented as median (interquartile range). Between-group comparisons were performed using the Mann–Whitney U test Abbreviations: HALP Hemoglobin, Albumin, Lymphocyte, and Platelet score, PNI Prognostic Nutritional Index, NLR Neutrophil-to-Lymphocyte Ratio, PLR Platelet-to-Lymphocyte Ratio, CRP C-reactive Protein, IQR Interquartile Range. p-values were calculated using the Mann–Whitney U test Table 2Multivariate logistic regression analysis for predictors of one-year HPV persistenceVariableOR95% CI (Lower–Upper)p-valueAge1.000.98–1.020.823Smoking0.970.61–1.550.904HPV16 (+)2.681.76–4.06< 0.001HPV18 (+)2.611.59–4.29< 0.001p16 (+)2.380.95–5.920.063Ki-67 (+)0.760.34–1.680.492HALP (per 1-SD increase)0.980.97–1.000.034PNI (per 1-SD increase)1.010.97–1.050.547NLR (per 1-SD increase)1.621.30–2.11< 0.001PLR (per 1-SD increase)0.990.98–1.000.002CRP (per 1-SD increase)0.980.95–1.010.135Multivariate logistic regression analysis for predictors of one-year HPV persistence. Odds ratios (OR) with 95% confidence intervals (CI) are presented. Continuous variables (HALP, PNI, NLR, PLR, CRP) were standardized using Z-score transformation (mean = 0, SD = 1) to address scale differences among predictors. A two-tailed p < 0.05 was considered statistically significants Multivariate logistic regression analysis for predictors of one-year HPV persistence Multivariate logistic regression analysis for predictors of one-year HPV persistence. Odds ratios (OR) with 95% confidence intervals (CI) are presented. Continuous variables (HALP, PNI, NLR, PLR, CRP) were standardized using Z-score transformation (mean = 0, SD = 1) to address scale differences among predictors. A two-tailed p < 0.05 was considered statistically significants Results The study included 470 HPV-positive patients in total. At the end of the follow-up, 271 patients tested negative (Group N, HPV clearance) and 199 remained positive (Group P, HPV persistence). Comparative analyses were performed between the two groups regarding demographic characteristics, laboratory parameters, and calculated HALP and PNI scores (Table 3). Histopathologic and immunohistochemical findings obtained from cervical biopsy and ECC specimens, including p16 and Ki-67 staining patterns, are summarized in Table 4. Table 3Comparison of demographic characteristics between groupsVariablesGroup N (n = 271)Group P (n = 199)p-valueAge (years), mean ± SD46.8 ± 9.647.5 ± 9.80.477Marital status (married, %)82.784.40.707Smoking (yes, %)26.924.10.523Contraceptive use (yes, %)38.036.70.183Gravidity ≥ 3 (%)78.376.20.365Parity ≥ 2 (%)79.080.90.637Mode of delivery (%)0.054*Nulliparous6.35.0Vaginal delivery56.554.8Cesarean section30.325.6Both NVD + CS7.014.6Chronic disease (yes, %)21.427.60.127Values are presented as mean ± standard deviation (SD) for continuous variables and as percentages for categorical variables. Student’s t-test was used for normally distributed continuous variables. Categorical variables were compared using the chi-square test or Fisher’s exact test, as appropriateAbbreviations: Group N HPV clearance group, Group P HPV persistence group, SD Standard Deviation, % Percentage *The p-value for mode of delivery was calculated using the chi-square test across four categories (Nulliparous, NVD, CS, NVD+CS) Comparison of demographic characteristics between groups Values are presented as mean ± standard deviation (SD) for continuous variables and as percentages for categorical variables. Student’s t-test was used for normally distributed continuous variables. Categorical variables were compared using the chi-square test or Fisher’s exact test, as appropriate Abbreviations: Group N HPV clearance group, Group P HPV persistence group, SD Standard Deviation, % Percentage *The p-value for mode of delivery was calculated using the chi-square test across four categories (Nulliparous, NVD, CS, NVD+CS) Table 4Histopathologic and immunohistochemical findings according to sampling method and groupParameterCategoryGroup N (n = 271)Group P (n = 199)Cervical biopsyNormal tissue173 (63.8%)121 (60.8%)Koilocytosis30 (11.1%)16 (8.0%)LSIL (CIN1)68 (25.1%)62 (31.2%)Overall p-value0.250Endocervical curettage (ECC)Normal tissue221 (81.6%)151 (75.9%)Koilocytosis8 (3.0%)10 (5.0%)LSIL (CIN1)41 (15.1%)35 (17.6%)Endometrial tissue1 (0.4%)3 (1.5%)Overall p-value0.269p16 stainingNegative242 (59.5%)165 (40.5%)Superficial29 (46.0%)34 (54.0%)Overall p-value0.045Ki-67 stainingNegative224 (59.1%)155 (40.9%)Positive47 (51.6%)44 (48.4%)Overall p-value0.196Values are presented as frequencies and percentages. Comparisons between groups were made using the chi-square test or Fisher’s exact test, as appropriateAbbreviations: Group N HPV clearance group, Group P HPV persistence group, % Percentage, ECC Endocervical curettage, LSIL Low-grade squamous intraepithelial lesion Histopathologic and immunohistochemical findings according to sampling method and group Values are presented as frequencies and percentages. Comparisons between groups were made using the chi-square test or Fisher’s exact test, as appropriate Abbreviations: Group N HPV clearance group, Group P HPV persistence group, % Percentage, ECC Endocervical curettage, LSIL Low-grade squamous intraepithelial lesion The distribution of one-year persistence rates by genotype revealed the highest persistence among HPV16 (55.6%) and HPV18 (56.3%) infections, compared with other high-risk types (33.8%) and low-risk types (21.0%) (Fig. 2). Distribution of HPV genotype outcomes at one-year follow-up. One-year persistence rates by genotype category. Bars display percentages with absolute case numbers (n). Categories: HPV16; HPV18 (excluding HPV16); other high-risk types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59; excluding HPV16/18); and low-risk types only (66, 68, Other; no concurrent high-risk types) Factors that may influence HPV persistence include HPV genotype, age, smoking status, and immune-related conditions. The mean ages of Group P and Group N were 47.50 ± 9.79 and 46.77 ± 9.58 years, respectively, with no statistically significant difference (p = 0.477). No significant differences were observed between groups in terms of age, marital status, smoking, contraceptive use, gravidity, parity, mode of delivery, or chronic diseases (Table 3). Although the p-value for mode of delivery was close to the threshold (p = 0.054), the difference was not statistically significant. In univariate analysis, p16 expression was significantly associated with HPV persistence (p = 0.045), whereas this association attenuated and did not remain significant after adjustment for HPV genotype, age, smoking status, and systemic inflammation/nutritional indices in the multivariate model (p = 0.063; Table 2; Fig. 3). Ki-67 showed no significant association in either analysis. Forest plot of multivariate logistic regression analysis for predictors of one-year HPV persistence. Forest plot of multivariate logistic regression analysis for predictors of one-year HPV persistence. Odds ratios (OR) with 95% confidence intervals (CI) are shown for each variable. HALP, PLR, and NLR were standardized using Z-score transformation (mean = 0, SD = 1) to address scale differences among continuous predictors. Blue markers indicate statistically significant associations (p < 0.05), whereas gray markers represent non-significant results (p ≥ 0.05). The vertical dashed line denotes the reference value (OR = 1) All patients were informed about HPV vaccination, and vaccination was left to patient preference. In Group P, 137 women were unvaccinated, while 43 received at least one dose (2 received one dose, 3 received two doses, and 38 completed three doses). In Group N, 193 women were unvaccinated, whereas 78 received at least one dose (1 received one dose, 3 received two doses, and 74 completed three doses). No significant difference was observed between groups in vaccination status (p = 0.604). At the one-year follow-up, only NLR differed significantly between the persistence and clearance groups, with higher values in the persistence group (p < 0.001; Fig. 4). In contrast, HALP, PNI, PLR, and CRP showed no significant group differences (all p > 0.05; Table 1). Subgroup analysis indicated that HALP values increased with age in the clearance group (≥ 40 vs. < 40 years, p = 0.036), but within each age stratum (< 40 and ≥ 40) there were no differences between persistence and clearance groups. Comparison of neutrophil-to-lymphocyte ratio (NLR) between clearance and persistence groups. Boxplots showing the distribution of NLR values in women with HPV clearance (Group N, n = 271) and HPV persistence (Group P, n = 199) at the one-year follow-up. The persistence group demonstrated significantly higher NLR values compared with the clearance group (median 1.54 vs. 1.16, p < 0.001) ROC analysis showed that NLR had modest discriminatory ability [AUC = 0.623 (95% CI: 0.573–0.673), p < 0.001; Fig. 5]. By comparison, HALP [AUC = 0.475 (95% CI: 0.422–0.528)], PNI [AUC = 0.487 (95% CI: 0.434–0.540)], PLR [AUC = 0.513 (95% CI: 0.460–0.566)], and CRP [AUC = 0.462 (95% CI: 0.409–0.515)] showed no discriminatory ability. Receiver operating characteristic (ROC) curves for systemic inflammation and nutritional indices. ROC curves for HALP, PNI, NLR, PLR, and CRP in predicting one-year HPV persistence. NLR demonstrated modest discriminatory ability [AUC = 0.623 (95% CI: 0.573–0.673), p < 0.001], whereas HALP [AUC = 0.475 (95% CI: 0.422–0.528)], PNI [AUC = 0.487 (95% CI: 0.434–0.540)], PLR [AUC = 0.513 (95% CI: 0.460–0.566)], and CRP [AUC = 0.462 (95% CI: 0.409–0.515)] showed no discriminatory ability. The diagonal line represents the reference line (AUC = 0.5) In the multivariate logistic regression model adjusted for HPV16, HPV18, age, smoking, and immunohistochemical parameters (Table 2), Z-standardized HALP, PLR, and NLR were analyzed together. As shown in Fig. 4, NLR remained a significant independent predictor of one-year HPV persistence, whereas standardized HALP and PLR demonstrated minor associations without clinical impact. Finally, multivariate logistic regression identified HPV16 and HPV18 positivity as the strongest independent predictors of one-year HPV persistence. Women with HPV16 were approximately 2.7 times more likely to have persistent infection, and those with HPV18 were 2.6 times more likely (both p < 0.001). Elevated standardized NLR (per 1-SD increase) was also independently associated with persistence (OR = 1.62, p < 0.001). Although standardized HALP and PLR reached statistical significance (p = 0.034 and p = 0.002, respectively), their effect sizes were small and without clinical relevance. P16 expression demonstrated a borderline association (p = 0.063), whereas Ki-67, PNI, CRP, age, and smoking status were not independent predictors (Table 2; Fig. 3). Discussion In this study, we evaluated the predictive value of systemic inflammation- and nutrition-based indices, including the HALP score and PNI, in relation to HPV persistence. Furthermore, a comprehensive examination of inflammatory hematologic and biochemical markers was performed, encompassing the NLR, PLR, and CRP. These parameters serve as key indicators between systemic inflammation with nutritional status. The findings showed no significant differences in HALP and PNI scores between the persistent and clearance groups. However, NLR values were found to be significantly higher in the persistent group. This suggests that inflammatory markers may have a higher value in predicting HPV persistence compared to nutrition-based indices. The observed difference between Tables 1 and 2 can be ascribed to the statistical procedures employed. Direct group comparisons did not reveal significant patterns; however, ROC and regression analysis indicated the potential predictive utility of HALP and PLR. Although the p-value was borderline, the difference was not statistically significant, suggesting that the mode of delivery does not impact HPV persistence. Similarly, no significant differences were observed in other demographic and reproductive characteristics, such as age, parity, smoking, or contraceptive use, indicating that clinical factors may have limited influence on persistence in this cohort. The HALP score has become a frequently utilized metric for evaluating systemic inflammatory processes in solid tumors in recent years [16, 17]. The albumin level reflects nutritional condition, while the platelet and lymphocyte counts are influenced by immune response and age-related factors. A prospective study including over 20,000 healthy adults indicated that a decline in platelet count after 60 years of age is associated with immune responses [18]. The inclusion of platelet count in the denominator of the HALP score suggests a potential correlation between this score and age. Previous studies evaluating the relationship between age and HPV infection have demonstrated that HPV clearance decreases with increasing age, indicating an inverse association between the two variables [19, 20]. The study revealed no statistically significant difference in HALP scores between persistent and negative groups, suggesting that these scores are not useful in predicting HPV status. The age distribution exhibited no significant disparities between the groups, thereby eliminating the possibility of confounding effects. Although the overall difference was insignificant, subgroup analyses notably that HALP scores were elevated in patients aged ≥ 40 years, particularly in the negative group. However, this discrepancy did not lead to a substantial alteration in the comparison between the primary groups. PNI is a score calculated based on albumin and lymphocyte levels, similar to the HALP score, which reflects both an individual’s nutritional status and immune response [21]. In cancer patients, systemic infections, and intensive care patients, the combined evaluation of these parameters has been shown to have prognostic value [22–24]. HPV infection is primarily localized in the cervical mucosa and is closely related to both systemic and mucosal immune responses [25]. Therefore, systemic indices such as HALP and PNI, which mainly reflect systemic inflammation, provide limited insight into the viral elimination process. These observations suggest that local immune mechanisms, including epithelial defense, antigen presentation, and cytokine networks, may play a more decisive role than systemic markers [26, 27]. The findings of this study indicate that NLR demonstrates modest discriminatory ability for predicting persistent HPV infection. A recent study of individuals who underwent conization identified a significant correlation between elevated NLR levels and adverse outcomes. For each unit rise in NLR, the probability of developing cancer increased by 37% [14]. A recent study also demonstrated that NLR and PLR exhibit a non-linear pattern, wherein low NLR levels have a protective effect, whereas elevated levels augment risk [28]. The results support the utilization of NLR as a simple and readily available biomarker indicative of inflammatory and immunological responses. However, we also emphasize the importance of considering clinical factors such as age and menopause when interpreting the results. The present study determined that PLR and CRP levels do not serve as predictors of HPV persistence. Nevertheless, current evidence suggests a potential correlation between elevated PLR and cervical preinvasive lesions, as well as malignancies, in certain studies. It is important to recognize that the evidence supporting this correlation is inconsistent and, often, less robust than the associations observed with other inflammatory markers [13]. No significant difference in CRP levels was observed between the groups. However, it has been indicated that CRP may indirectly facilitate the persistence of infection by indicating systemic inflammation in HPV-positive women [29]. Our study examined histopathological and immunohistochemical markers associated with cervical preinvasive lesions and HPV persistence. In the literature, p16 and Ki-67 are considered highly specific, particularly for distinguishing high-grade cervical lesions (CIN2 and above) when co-expressed [30]. In our cohort, p16 expression showed an association with HPV persistence, whereas Ki-67 did not demonstrate significant prognostic value. Similarly, previous studies have emphasized that Ki-67 alone has limited utility, but its co-expression with p16 provides stronger prognostic significance, especially in high-grade lesions (CIN2 and above) [31]. This finding may be related to the fact that the majority of cases in the present study consisted of patients with low-grade lesions or normal histopathological findings that did not require excisional procedures. In the present study, CIN2 lesions were identified in four patients; however, these patients were placed under follow-up as they refused excisional treatment. In most of the other cases, biopsy and ECC results were limited to chronic cervicitis, koilocytosis, or low-grade lesions such as CIN1. It is important to note that markers such as p16 and Ki-67 demonstrate their greatest diagnostic and prognostic value in preinvasive or invasive cervical lesions, whereas their relevance is limited in transient infections. Hence, in evaluating persistent HPV infection, reliance on histopathological findings alone is inadequate. A comprehensive approach integrating immunological and molecular parameters is necessary. The majority of individuals infected with HPV will recover within one to two years. In specific cases, the virus persists and may lead to cervical precancerous lesions [32]. Several variables contribute to the initiation of persistent infection, including the carcinogenic potential of the HPV type, age, immunosuppression, smoking, and co-infections [33]. E6 and E7 oncoproteins in high-risk types like HPV16 and HPV18 suppress the immune response, hindering viral elimination and contributing to HPV persistence [34]. High-risk types inhibit the immune response via E6 and E7 oncoproteins, thereby obstructing viral clearance; yet, these proteins were not assessed in the present investigation. The findings of this study corroborate the clinical significance of immune evasion mechanisms and suggest that HPV16/18 positivity may function as an independent risk factor for persistence. The preponderance of CC cases worldwide has been linked to persistent HPV 16 and 18 infections [25, 35]. HPV vaccines, available since 2006, are effective only before viral exposure and have no therapeutic effect on existing infections [35]. In our country, they are not included in the national immunization program and are administered individually. In this study, all vaccinated patients received the vaccine after testing HPV-positive, yet the rates of HPV negativity at one year were similar between vaccinated and unvaccinated groups, consistent with literature indicating limited efficacy of HPV vaccines in clearing existing infections. Multivariate regression analysis confirmed that HPV16 and HPV18 positivity were the strongest independent predictors of one-year HPV persistence, in line with their well-established oncogenic role. In the present study, standardized HALP, PLR, and NLR values were used in multivariate analyses to minimize the effect of scale differences among continuous predictors. This approach allowed a more accurate comparison of systemic inflammation and nutritional indices and confirmed that NLR remained the only independent predictor of HPV persistence. Although HALP and PNI have recognized prognostic value in malignant diseases, in this cohort they did not distinguish between clearance and persistence. Higher NLR values were associated with persistence, supporting the idea that this simple index could contribute some value, even if it is insufficient on its own. Regarding immunohistochemical markers, p16 showed an association with persistence in univariable analysis, but this relationship did not remain significant in the multivariable model, suggesting that p16 may not act as an independent predictor. By contrast, Ki-67 had no prognostic relevance, consistent with earlier studies indicating that p16/Ki-67 co-expression is mainly useful in high-grade lesions. Vaccination given after diagnosis did not alter clearance rates, underscoring its preventive rather than therapeutic function. Overall, HPV genotype remains the principal determinant of persistence, while NLR may provide limited additional information. Further research integrating systemic and local immune markers, supported by external validation, is warranted to establish stronger predictive models. This study has several strengths. It is based on a relatively large sample of 470 HPV-positive women, providing sufficient statistical power to detect clinically meaningful differences. In addition, the study design incorporated both systemic indices (HALP, PNI, NLR, PLR, CRP) and immunohistochemical markers (p16 and Ki-67), allowing a more comprehensive evaluation of predictors of HPV persistence. Finally, the inclusion of real-world data from a national cervical cancer screening program enhances the applicability of the findings to daily clinical practice. This study has several limitations. First, its retrospective design and single-center setting may restrict the generalizability of the findings. In addition, the follow-up period was limited to one year, which precludes assessment of long-term outcomes. Although we expanded our analyses to include additional hematologic parameters such as NLR, PLR, and CRP in addition to HALP and PNI, more detailed immunological markers (e.g., peripheral T-cell subsets) were not available in our dataset and could not be evaluated. Taken together, while our study highlights the limited predictive value of systemic indices, it also emphasizes the need for future investigations that integrate local immune responses and molecular markers. Conclusions Systemic inflammation- and nutrition-based indices, such as HALP and PNI, exhibited no discriminatory potential in predicting one-year HPV persistence. Conversely, the NLR demonstrated a substantial correlation with persistence and exhibited modest discriminatory capability. This finding suggests a potential role for NLR as a complementary biomarker, though it is inadequate as a standalone predictor. HPV16 and HPV18 positivity was confirmed as the strongest independent risk factors, consistent with their well-established oncogenic potential and immune evasion mechanisms. Post-diagnosis HPV vaccination demonstrated no influence on clearance rates, thereby underscoring its preventive rather than therapeutic role. These findings emphasize the need for more studies integrating systemic and local immune markers, with external validation, to develop more robust prognostic models for HPV-related disease. Acknowledgements The authors would like to thank all participants who contributed to this study. Abbreviations Human papillomavirus Cervical cancer C-reactive protein Cervicovaginal cytology (Pap test) Cervical intraepithelial neoplasia Prognostic Nutritional Index Neutrophil-to-lymphocyte ratio Hemoglobin, albumin, lymphocyte count, and platelet count values Low-grade squamous intraepithelial lesions High-grade squamous intraepithelial lesions Endocervical curettage Area under the curve Receiver operating characteristic Authors’ contributions FO: Conceptualization, validation and formal analysis, data collection, statistical analysis, writing—original draft, funding acquisition.BO: Data collection, writing—original draft.BE: Data collection, writing.All authors read and approved the final manuscript. Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Data availability The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This study was approved by the Ethics Committee of Ordu University (Ethics Committee Decision 2025/152, Date: 25.04.2025). All participants provided written informed consent before participation. The study was conducted in accordance with the Declaration of Helsinki. Consent for publication Not applicable. No identifying images or personal/clinical details that compromise anonymity are included. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Change history 8/3/2026 The original online version of this article was revised due to update the author ORCID ID. References Associated Data Data Availability Statement The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.